RECORD // Company

Sunshine Biopharma Inc.

Formerly: Sunshine Biopharma, Inc; Mountain West Business Solutions, Inc; mountain west business solutions,inc; mountain state business solutions,inc

Built 2026-11-22T01:17:28Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (2 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

Gleif lei (1)
SEC EDGAR (1)

3 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-12 · accession 0001683168-26-008624

ItemValuePeriodFormFiledAccessionReport
Revenue$9,442,3253 months ended 2026-09-3010-Q2026-11-120001683168-26-0086242026-11-22 01:17 UTCReport an error
Net income (loss)$-1,223,9403 months ended 2026-09-3010-Q2026-11-120001683168-26-0086242026-11-22 01:17 UTCReport an error
Cash and cash equivalents$14,618,614at 2026-09-3010-Q2026-11-120001683168-26-0086242026-11-22 01:17 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001402328
Ticker
SBFM
EIN
205566275
CUSIP
867781809
Record ID
sx:sec:0001402328

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

31 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-18SEC EDGAR company profile2026-11-22 01:17 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-18SEC EDGAR company profile2026-11-22 01:17 UTCReport an error
State of incorporationCO2026-11-18SEC EDGAR company profile2026-11-22 01:17 UTCReport an error
Fiscal year end (MMDD)12312026-11-18SEC EDGAR company profile2026-11-22 01:17 UTCReport an error
Business address333 LAS OLAS WAY, CU4 SUITE 433, FORT LAUDERDALE, FL, 333012026-11-18SEC EDGAR company profile2026-11-22 01:17 UTCReport an error
ExchangesNasdaq, Nasdaq2026-11-18SEC EDGAR company profile2026-11-22 01:17 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$36,305,8912025-12-3110-K, XBRL Revenues2026-11-22 01:17 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-5,975,3522025-12-3110-K, XBRL NetIncomeLoss2026-11-22 01:17 UTCReport an error
Total assets (at 2025-12-31)$30,079,1672025-12-3110-K, XBRL Assets2026-11-22 01:17 UTCReport an error
Stockholders' equity (at 2025-12-31)$23,038,4602025-12-3110-K, XBRL StockholdersEquity2026-11-22 01:17 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$9,123,3082025-12-3110-K, XBRL CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents2026-11-22 01:17 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-5,331,0732025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 01:17 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$174,4912025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-22 01:17 UTCReport an error
Form D total offering amount (D filed 2023-05-17)$4,996,4972023-05-17D2026-11-22 01:17 UTCReport an error
Form D total amount sold (D filed 2023-05-17)$4,996,4972023-05-17D2026-11-22 01:17 UTCReport an error
Form D industry groupPharmaceuticals2023-05-17D2026-11-22 01:17 UTCReport an error
Form D revenue rangeDecline to Disclose2023-05-17D2026-11-22 01:17 UTCReport an error
Form D date of first sale2023-05-122023-05-17D2026-11-22 01:17 UTCReport an error
8-K Item 5.07, Submission of Matters to a Vote of (filed 2026-10-14)Security Holders. On October 13, 2026, Dr. Steve N. Slilaty, as the holder of the majority of the voting power of the stockholders of Sunshine Biopharma Inc. (the “Company”), approved by written consent: · to issue in excess of twenty percent (20%) of the outstanding shares of the Company’s common stock at a deemed discount to the Nasdaq Minimum Price (as defined in Nasdaq Listing Rule 5635(d)(1)(A)) immediately prior to execution of the Placement Agent Agreement for the Company’s public offering that closed on October 9, 2026 (the “Offering”). · to any adjustment to the exercise price or number of shares of common stock underlying the Series D Warrants issued in the Offering in the event…2026-10-14SEC EDGAR 8-K 0001683168-26-007845 (text as filed, excerpt)2026-11-22 01:17 UTCReport an error
8-K Item 1.01, Entry into a Material Definitive (filed 2026-10-09)Agreement. On October 8, 2026, Sunshine Biopharma Inc. (the “Company”) entered into a placement agent agreement (the “Placement Agent Agreement”) with Aegis Capital Corp. (the “Placement Agent”), in connection with a best efforts public offering (the “Offering”) of (A) 10,509,082 common units (the “Common Units”), each consisting of (i) one share of the Company’s common stock, par value $0.001 per share (“Common Stock”), and (ii) two Series D warrants (the “Series D Warrants”), each exercisable for one share of Common Stock; and (B) 400,000 pre-funded units (the “Pre-Funded Units”), each consisting of (i) one pre-funded warrant (the “Pre-Funded Warrants”) to purchase one share of Common…2026-10-09SEC EDGAR 8-K 0001683168-26-007758 (text as filed, excerpt)2026-11-22 01:17 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-10-09)On October 8, 2026, the Company issued a press release announcing the pricing of the Offering. A copy of the press release is filed as Exhibit 99.1 to this report. On October 9, 2026, the Company issued a press release announcing the closing of the Offering. A copy of the press release is filed as Exhibit 99.2 to this report. Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Placement Agent Agreement 10.2 Form of Pre-Funded Warrant 10.3 Form of Series D Warrant 99.1 Press Release, dated October 8, 2026 99.2 Press Release dated October 9, 2026 104 Cover Page Interactive Data File (formatted in Inline XBRL). 32026-10-09SEC EDGAR 8-K 0001683168-26-007758 (text as filed, excerpt)2026-11-22 01:17 UTCReport an error
8-K Item 5.07, Submission of Matters to a Vote of (filed 2026-09-16)Security Holders. On September 15, 2026, Dr. Steve N. Slilaty, as the holder of the majority of the voting power of the stockholders of Sunshine Biopharma Inc. (the “Company”), approved by written consent authorizing the Company’s board of directors to effect a reverse split of the Company’s common in a ratio of up to 1-for-20, with the board of directors having the discretion as to whether or not the reverse split is to be effected, and with the exact ratio of any reverse split to be set at a whole number up to 1-for-20 as determined by the board in its discretion. The shareholder consent will be effective 20 days after the definitive information statement relating to such consent is…2026-09-16SEC EDGAR 8-K 0001683168-26-007193 (text as filed, excerpt)2026-11-22 01:17 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-09-11)As of the date of filing of this report, due to recent sales of Sunshine Biopharma Inc.’s (the “Company”) common stock under the Company’s previously disclosed at-the-market offering, the exercise price of the Company’s outstanding Series B Warrants has been reduced to $1.2046, subject to further adjustment as set forth under the Series B Warrants. 22026-09-11SEC EDGAR 8-K 0001683168-26-007090 (text as filed, excerpt)2026-11-22 01:17 UTCReport an error
Largest institutional holder #1 (13F as filed): JANE STREET GROUP, LLC$31,4452026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 01:17 UTCReport an error
Largest institutional holder #2 (13F as filed): SBI Securities Co., Ltd.$3402026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 01:17 UTCReport an error
Largest institutional holder #3 (13F as filed): NATIONAL BANK OF CANADA /FI/$102026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 01:17 UTCReport an error
Largest institutional holder #4 (13F as filed): OSAIC HOLDINGS, INC.$42026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 01:17 UTCReport an error
Largest institutional holder #5 (13F as filed): Caitong International Asset Management Co., Ltd$22026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 01:17 UTCReport an error
Largest institutional holder #6 (13F as filed): Farther Finance Advisors, LLC$22026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 01:17 UTCReport an error
Largest institutional holder #7 (13F as filed): Strive Financial Group ,LLC$22026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 01:17 UTCReport an error
Largest institutional holder #8 (13F as filed): TD Waterhouse Canada Inc.$22026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 01:17 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.